Exploring Targeted-Release Budesonide for IgA Nephropathy: A Comprehensive Review

Exploring Targeted-Release Budesonide for IgA Nephropathy: A Comprehensive Review

The article discusses the potential use of targeted-release budesonide (TRF-budesonide) in treating IgA nephropathy (IgAN), a common kidney disease characterized by IgA deposits in the kidneys. IgAN can lead to end-stage renal disease, and current treatments like ACE inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) aren’t always effective in slowing disease progression.

Merilog Becomes First FDA-Approved Rapid-Acting Insulin Biosimilar for Diabetes Care

Merilog Becomes First FDA-Approved Rapid-Acting Insulin Biosimilar for Diabetes Care

The U.S. Food and Drug Administration (FDA) has approved Merilog (insulin-aspart-szjj), a Novolog (insulin aspart) biosimilar, for the control of glycemia in adults and pediatric patients with diabetes mellitus. Merilog is the first FDA-approved rapid-acting insulin biosimilar and is available as a 3 mL prefilled pen and a 10 mL multiple-dose vial. Merilog reduces mealtime blood sugar surges, allowing for improved control of diabetes.

AACE Releases Updated Guidance on Dyslipidemia Drug Therapy

AACE Releases Updated Guidance on Dyslipidemia Drug Therapy

The American Association of Clinical Endocrinology (AACE) has introduced a new guideline for managing dyslipidemia, which refers to abnormal cholesterol levels. This guideline provides evidence-based recommendations for newer drug therapies and emphasizes patient-centered outcomes, particularly the reduction of cardiovascular disease (CVD) risk. It is intended for adults aged 18 and older who have dyslipidemia or high triglycerides and are already receiving standard treatment but may need additional medications.